The U.S. Food and Drug Administration (FDA) has authorized Philip Morris-owned Swedish Match to market 20 Zyn nicotine pouch products as modified-risk tobacco products. This regulatory decision permits the company to claim that switching from cigarettes to Zyn lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis. While the FDA allows this marketing claim, the agency maintains that there is no safe tobacco product and warns that adults who do not use tobacco products should not start.
Regulatory Context and Modified Risk Status
The FDA’s authorization specifically applies to the company’s ability to substantiate health-related claims regarding disease risk reduction.
The agency continues to emphasize that there is no safe tobacco product, that youth should not use tobacco products and that adults who do not use tobacco products should not start. The decision follows a review of data provided by Swedish Match.
Scope of the Authorized Products
The authorization covers a broad range of Zyn varieties currently available to adult consumers. The products included in the order are:
- Zyn Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, and Wintergreen.
- Each of these flavors is authorized in both 3-milligram and 6-milligram nicotine strengths.
These products are placed between the user’s gum and lip, delivering nicotine without tobacco. As cigarette sales continue to decline in the U.S., major tobacco companies have shifted focus toward smoke-free products.
Industry Trends and Public Policy
The rise of nicotine pouches has coincided with a shift in the political and regulatory landscape regarding nicotine products. The current administration has taken a more industry-friendly approach, including by creating a pathway for some flavored e-cigarettes and nicotine pouches to remain on the market while they undergo FDA review.
This policy pivot has drawn significant attention to the role of nicotine pouches in both public health and modern culture. As reported by The Wall Street Journal, the use of nicotine pouches has become a subject of interest within high-level government circles, including among officials such as Health and Human Services Secretary Robert F. Kennedy Jr.
Comparison of Regulatory Milestones
The recent FDA order represents a distinct progression from previous authorizations:
| Milestone | Scope of Authorization | Marketing Capability |
|---|---|---|
| January 2025 Authorization | Market access for 20 Zyn products. | Standard retail sales only. |
| Tuesday’s Order | Expanded regulatory status for the same 20 products. | Allowed to state reduced risk of specific diseases. |
By moving from simple market authorization to a modified-risk claim, Philip Morris gains a significant competitive advantage in the nicotine market. The ability to cite a reduced risk of diseases like emphysema and stroke serves as a marketing tool as the company attempts to capture a larger share of the adult consumer base.
Despite this, the FDA remains firm in its stance regarding youth prevention. The agency has said there is no safe tobacco product, that youth should not use tobacco products and that adults who do not use tobacco products should not start.
Keep reading